
Hot
Regulators have fast-tracked the approval of daraxonrasib for pancreatic cancer. While the decision is being hailed as a major shift, detailed clinical data on its long-term efficacy remains sparse.
#AjakoTaja#TrendingNews#WorldNews
1m readAI
BBC News+1

